ORIGINAL RESEARCH article
Front. Oncol., 29 March 2023
Sec. Cancer Imaging and Image-directed Interventions
Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1136366
RETRACTED: A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
- QY
Qing Yang 1†
- GL
Gengyu Li 1†
- XW
Xiaoqiu Wu 1
- HL
Haiying Lin 1
- WW
Wanrui Wu 2
- XX
Xiangpang Xie 2
- YZ
Yu Zhu 2
- WC
Wei Cai 2
- CS
Changsheng Shi 2*
- SZ
Shengye Zhuo 1*
1. Department of Gastroenterology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
2. Interventional vascular Surgery, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
Summary
Citation
Yang Q, Li G, Wu X, Lin H, Wu W, Xie X, Zhu Y, Cai W, Shi C and Zhuo S (2023) RETRACTED: A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma. Front. Oncol. 13:1136366. doi: 10.3389/fonc.2023.1136366
Received
03 January 2023
Accepted
20 March 2023
Published
29 March 2023
Volume
13 - 2023
Edited by
Min Tang, Jiangsu University, China
Reviewed by
Lu Zhang, Biogen Idec, United States; Nian Jiang, University of Tsukuba, Japan
Updates
†These authors have contributed equally to this work and share first authorship
This article was submitted to Cancer Imaging and Image-directed Interventions, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.